Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade.

Shekarian T, Sivado E, Jallas AC, Depil S, Kielbassa J, Janoueix-Lerosey I, Hutter G, Goutagny N, Bergeron C, Viari A, Valsesia-Wittmann S, Caux C, Marabelle A.

Sci Transl Med. 2019 Oct 23;11(515). pii: eaat5025. doi: 10.1126/scitranslmed.aat5025.

PMID:
31645452
2.

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.

Clémenceau B, Valsesia-Wittmann S, Jallas AC, Vivien R, Rousseau R, Marabelle A, Caux C, Vié H.

J Immunol Res. 2015;2015:482089. doi: 10.1155/2015/482089. Epub 2015 Nov 17.

3.

TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.

Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Bénard J, Puisieux A, Marabelle A, Valsesia-Wittmann S.

Cancer Lett. 2015 Feb 1;357(1):412-418. doi: 10.1016/j.canlet.2014.11.056. Epub 2014 Dec 1.

PMID:
25475555
4.

Upstream ORF affects MYCN translation depending on exon 1b alternative splicing.

Besançon R, Valsesia-Wittmann S, Locher C, Delloye-Bourgeois C, Furhman L, Tutrone G, Bertrand C, Jallas AC, Garin E, Puisieux A.

BMC Cancer. 2009 Dec 17;9:445. doi: 10.1186/1471-2407-9-445.

5.

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P, Puisieux A.

Cancer Cell. 2004 Dec;6(6):625-30.

Supplemental Content

Loading ...
Support Center